BRAF and thyroid gland carcinoma: Valproic acid in combination with the Ras inhibitor farnesylthiosalicylic acid (FTS) showed synergistic antiproliferative activity against BRAF-mutant ARO thyroid cancer cells, which was accompanied by suppression of Ras, survivin, and aurora A, leading to a mitotic crisis [Table 3][103].